ABSTRACT
Objective To investigate the antiangiogenic effect of galangin in vitro and in vivo.Methods The inhibitory ef?fect of galangin on human umbilical vein endothelial cells(EaHy926)was tested by sulphorhodamine(SRB)method,the EaHy926 endothelial cell migration was assessed using in vitro model system,and the in vivo antiangiogenic effect of galangin at 1,5 and 10 μg was evaluated using the chorioallantoic membrane(CAM)model.The H22 tumor-bearing model was established using BALB/c nude mice,which were divided into five groups:The model group,positive control group〔ip cyclophosphamide 20 mg/(kg·d)〕and the galangin 10,20 and 40 mg/(kg·d)groups,respectively.After the daily administration for 15 consecutive days,the tumors grown in the nude mice were examined and the microvessel density(MVD)was tested via examining the expression of CD31 in the tumor tissues by immunohistochemistry in order to evaluate the effect of galangin to the tumor growth and the angiogenesis of the tumors. Result Galangin inhibited both the growth,migration and Matrigal tubule of EaHy926 cells in a dose-dependent manner in the in vitro test. Further in the in vivo test,galangin could also obviously inhibit the angiogenesis of CAM at the 5 and 10 μg concentration.The tumor mass and the relative tumor volume in the 20 and 40 mg/(kg·d)galangin groups and the positive control cyclophosphamide group were significantly lower(P<0.05)than those in the model group in the in vivo nude mice test. The tumor inhibitory rates of those three groups were 34.17%,79.73% and 55.75%,respectively.The MVD was also significantly lower in the high dosage galangin groups than that in the model group. Conclusion Galangin showed the obvious anti-angiogenenic effect both in vitro and in vivo in the present study.